| Characteristics |
Cascinu 95 |
Cunningham 98 |
Glimelius 97 |
Scheithauer 93 |
| Country/Location of first author |
Italy |
UK |
Sweden |
Austria |
| Baseline characteristics |
Reported |
Reported |
Reported |
Reported |
| Inclusion criteria |
Reported |
Reported |
Reported |
Reported |
| Exclusion criteria |
Not reported |
Reported |
Reported |
Not reported |
| Ethics committee approval stated |
Not reported |
Not reported |
Not reported |
Not reported |
| Adverse effects/side effects |
Reported |
Reported |
Reported |
Reported |
| Description of withdrawals and dropouts |
Reported |
Reported |
Reported |
Reported |
| Power calculation |
Reported |
Reported |
Not reported |
Not reported |
| Validation of instruments |
Not included a QOL assessment in this trial. |
QOLwas assessed with EORTC QLQ‐C30 questionnaire (including five function scales, one global health status scale, and nine symptom scales), which was filled in at baseline, 3 and 6 weeks and then every 6 weeks. |
QOL assessments were performed using EORTC‐QLQ C30 version 1.0. |
QOL was assessed at entry and every 2 months with the Functional Living Index for Cancer (FLIC‐authors used several refinements to FLIC scale). |
| Analysis |
Analysis was performed according to intention to treat |
Analysis was performed according to intention to treat |
Analysis was performed according to intention to treat |
Analysis was performed according to intention to treat |
